It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Prolactinomas represent the most common type of secretory pituitary neoplasms, with a therapeutic management that varies considerably based on tumour size and degree of hyperprolactinemia. The aim of the current study was to evaluate the relationship between serum prolactin (PRL) concentrations and prolactinoma size, and to determine a cut-off PRL value that could differentiate micro- from macro-prolactinomas. A retrospective cohort study of 114 patients diagnosed with prolactinomas between 2007 and 2017 was conducted. All patients underwent gadolinium enhanced pituitary MRI and receiver operating characteristic (ROC) analyses were performed. 51.8% of patients in this study were men, with a mean age at the time of diagnosis of 42.32 ± 15.04 years. 48.2% of the total cohort were found to have microadenomas. Baseline serum PRL concentrations were strongly correlated to tumour dimension (r = 0.750, p = 0.001). When performing the ROC curve analysis, the area under the curve was 0.976, indicating an excellent accuracy of the diagnostic method. For a value of 204 μg/L (4338 mU/L), sensitivity and specificity were calculated at 0.932 and 0.891, respectively. When a cut off value of 204 μg/L (4338 mU/L) was used, specificity was 93.2%, and sensitivity 89.1%, acceptable to reliably differentiate between micro- and macro- adenomas.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 University Hospitals Coventry and Warwickshire NHS Trust, Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), Coventry, UK (GRID:grid.15628.38)
2 University of Athens, 1st Department of Propaedeutic Internal Medicine, Endocrine Unit, National and Kapodistrian, Athens, Greece (GRID:grid.5216.0) (ISNI:0000 0001 2155 0800)
3 Achilles Information Limited, Abingdon, UK (GRID:grid.5216.0)
4 King’s College Hospital NHS Foundation Trust, Department of Endocrinology ASO/EASO COM, London, UK (GRID:grid.429705.d) (ISNI:0000 0004 0489 4320)
5 University Hospitals Coventry and Warwickshire NHS Trust, Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), Coventry, UK (GRID:grid.15628.38); University of Warwick, Division of Reproductive Health, Warwick Medical School, Coventry, UK (GRID:grid.7372.1) (ISNI:0000 0000 8809 1613); Aston University, Aston Medical Research Institute, Aston Medical School, Birmingham, UK (GRID:grid.7273.1) (ISNI:0000 0004 0376 4727)
6 King’s College Hospital NHS Foundation Trust, Department of Endocrinology ASO/EASO COM, London, UK (GRID:grid.429705.d) (ISNI:0000 0004 0489 4320); University of Warwick, Division of Reproductive Health, Warwick Medical School, Coventry, UK (GRID:grid.7372.1) (ISNI:0000 0000 8809 1613); King’s College London, Department of Obesity, Immunometabolism and Diabetes, School of Life Course Sciences, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)